User:Mr. Ibrahem/Levomepromazine

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Levomepromazine
Clinical data
Trade namesNozinan, Levoprome, Detenler, Hirnamin, Levotomin, Neurocil, others
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  • Only if needed
Routes of
administration		By mouth, IV, SC, IM[1]
Drug classTypical antipsychotic
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability~50–60%
MetabolismLiver
Onset of action0.5 to 3 hr[2]
Elimination half-life~20 hours
Duration of action8 hr[2]
ExcretionIn feces and urine (metabolites), unchanged drug only 1%
Identifiers
  • (2R)-3-(2-Methoxyphenothiazine-10-yl-)-N,N,2-trimethylpropanamine
Chemical and physical data
FormulaC19H24N2OS
Molar mass328.47 g·mol−1
3D model (JSmol)
  • O(c2cc1N(c3c(Sc1cc2)cccc3)C[C@H](C)CN(C)C)C
  • InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1 checkY
  • Key:VRQVVMDWGGWHTJ-CQSZACIVSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Levomepromazine, also known as methotrimeprazine, is a medication used for schizophrenia and palliative care.[1] In palliative care it is used for restlessness, pain, and vomiting.[1] It may be used by mouth or by injection.[1] Effects generally begin around 0.5 to 3 hours and last for 8 hours.[2]

Side effects may include low blood pressure with standing, sleepiness, dry mouth, liver problems, and dystonia.[2][1] Serious side effect may include priapism, QT prolongation, and neuroleptic malignant syndrome.[2][1][3] It is an antipsychotic of the phenothiazine type.[2] It works by blocking a variety of receptors, including adrenergic, dopamine, histamine, muscarinic acetylcholine, and serotonin.[2]

Levomepromazine was patented in 1954 and come into medical use in the United State in 1957.[4] It is available as a generic medication.[1] In the United Kingdom 84 tablets of 25 mg costs the NHS about £20 as of 2020.[1] It has been widely used;[2] though is no longer commercially available in the United States.[5]

References[edit]

  1. ^ a b c d e f g h i j BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 460. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  2. ^ a b c d e f g h i Dietz, I; Schmitz, A; Lampey, I; Schulz, C (19 January 2013). "Evidence for the use of Levomepromazine for symptom control in the palliative care setting: a systematic review". BMC palliative care. 12: 2. doi:10.1186/1472-684X-12-2. PMID 23331515.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  3. ^ "Levomepromazine Hydrochloride 25mg/ml Solution for Injection - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Archived from the original on 28 August 2021. Retrieved 13 August 2021.
  4. ^ Buschmann, Helmut; Holenz, Jörg; Párraga, Antonio; Torrens, Antoni; Vela, José Miguel; Díaz, José Luis (16 April 2007). Antidepressants, Antipsychotics, Anxiolytics, 2 Volume Set: From Chemistry and Pharmacology to Clinical Application. John Wiley & Sons. p. 502. ISBN 978-3-527-31058-6. Archived from the original on 28 August 2021. Retrieved 13 August 2021.
  5. ^ "Drugs@FDA: FDA-Approved Drugs". www.accessdata.fda.gov. Archived from the original on 24 March 2021. Retrieved 13 August 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Levomepromazine&oldid=1163539835"